Publication: Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
Issued Date
2012-10-01
Resource Type
ISSN
10970142
0008543X
0008543X
Other identifier(s)
2-s2.0-84866487544
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer. Vol.118, No.19 (2012), 4759-4767
Suggested Citation
David A. Reardon, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, Roger McLendon, Sith Sathornsumetee, Jeremy N. Rich, Eric S. Lipp, Dorothea Janney, Henry S. Friedman Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. Vol.118, No.19 (2012), 4759-4767. doi:10.1002/cncr.26541 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/13603
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
Other Contributor(s)
Abstract
BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendroglioma cohorts. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg per day for patients not on enzyme-inducing antiepileptic drugs (EIAEDs) and at 500 mg twice a day if on EIAEDs. The primary endpoint was progression-free survival at 12 months (PFS-12) and secondary endpoints were safety, median progression-free survival, and radiographic response rate. RESULTS: Thirty-Two patients were enrolled into each cohort. Eleven patients (17%) had before radiotherapy and 24 (38%) had received before chemotherapy. The median PFS and PFS-12 were 11 months and 39%, respectively. Outcome did not differ between the histologic cohorts. No patient achieved a radiographic response. The most common grade 3 or greater adverse events were neutropenia (11%), thrombocytopenia (3%), and diarrhea (3%). CONCLUSIONS: Imatinib plus hydroxyurea was well tolerated among recurrent/progressive LGG patients but this regimen demonstrated negligible antitumor activity. © 2012 American Cancer Society.